Overview

A Study of RC48-ADC Combined With Cadonilimab（AK104）in the Treatment of HER2-expression Locally Advanced or Metastatic Urothelial Carcinoma

Status:
Recruiting

Trial end date:
2026-04-01

Target enrollment:

Participant gender:

Summary

This study will evaluate the efficacy and safety of RC48-ADC combined with AK104 in HER2-expression locally advanced or metastatic urothelial carcinoma.

Phase:

Phase 2

Details

Lead Sponsor:

Shanxi Province Cancer Hospital

Collaborator:

Cancer Institute and Hospital, Chinese Academy of Medical Sciences